Eni has been granted a patent for a process to prepare a disubstituted diaryloxybenzoheterodiazole compound, defined by a specific general formula. This innovation outlines a method for synthesizing this compound, which may have various applications in chemical and pharmaceutical industries. GlobalData’s report on Eni gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Eni, Microscale biofuel reactors was a key innovation area identified from patents. Eni's grant share as of July 2024 was 65%. Grant share is based on the ratio of number of grants to total number of patents.
The patent US12060348B2 outlines a detailed process for synthesizing disubstituted diaryloxybenzoheterodiazole compounds, characterized by a specific general formula (I). The synthesis involves multiple steps, each with defined conditions regarding reactant ratios, catalysts, solvents, and temperatures. In the initial step (a), a halogenated benzoheterodiazole compound and a 2-thienylboronic compound are reacted in molar ratios ranging from 1:2 to 1:4, utilizing palladium-based catalysts and organic bases. The process is conducted under controlled temperatures (25° C. to 80° C.) and time frames (20 to 60 minutes), with the potential inclusion of non-ionic surfactants and hydrocarbon solvents to enhance the reaction environment.
Subsequent steps (b) through (d) further refine the synthesis, incorporating various organic bases, solvents, and crown ethers to facilitate the reactions. Each step specifies molar ratios for the reactants, the use of specific solvents (including dipolar aprotic solvents), and the application of palladium catalysts. The temperature and duration for each step are also meticulously defined, ensuring optimal conditions for the formation of the desired disubstituted diaryloxybenzoheterodiazole compound. The comprehensive nature of these claims highlights the patent's focus on precise chemical processes, which may have implications for the development of new materials or pharmaceuticals based on these compounds.
To know more about GlobalData’s detailed insights on Eni, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
